Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
- 20 December 2005
- journal article
- Published by Wiley in BJU International
- Vol. 97 (4) , 691-697
Abstract
OBJECTIVES: To determine, in preclinical in vivo animal and in clinical studies, whether raloxifene (a selective oestrogen‐receptor (ER) modulator that targets ER‐β and induces apoptosis in vitro in androgen‐independent prostate cancer, AIPC cells) affects prostate cell differentiation, proliferation and carcinogenesis, and in the pilot phase II clinical trial, the response rate and duration of patients with AIPC treated with a daily oral dose of raloxifene. PATIENTS, MATERIALS AND METHODS: Tumour proliferation rate in response to raloxifene treatment, and molecular markers of cell cycle and apoptosis, were evaluated in established ER‐β‐positive androgen‐dependent (AD) CWR22 and AI CWRSA9 human xenograft prostate cancer models. Twenty‐one patients with AIPC and evidence of disease progression were enrolled into the clinical trial and given daily oral raloxifene. RESULTS: There was significant growth inhibition by raloxifene in the ADPC and AIPC xenograft models (CWR22 68%, P < 0.010; CWRSA9 64%, P < 0.001), with no tumour regression. There was evidence of G1 arrest by increased p27kip1 expression in the raloxifene‐treated group. Eighteen patients comprised the efficacy analysis, as three withdrew before the first evaluation. At the first evaluation, five men had stable disease and continued on the study for a median of five cycles. The longest response was 17 cycles. Drug related toxicity was minimal. CONCLUSION: Raloxifene has activity in xenograft models, slowing disease progression. This translated to possible disease stabilization in patients with AIPC. Further studies are warranted.Keywords
This publication has 18 references indexed in Scilit:
- The Androgen Derivative 5α-Androstane-3β,17β-Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor β SubtypeCancer Research, 2005
- Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitorCarcinogenesis, 2005
- Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors α and βJournal of Biological Chemistry, 2005
- Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly menEuropean Journal of Endocrinology, 2004
- Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeNew England Journal of Medicine, 2003
- Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer CellsJournal of Biological Chemistry, 2002
- Estradiol in elderly menThe Aging Male, 2002
- Differential Expression of Estrogen Receptor β (ERβ) and Its C-Terminal Truncated Splice Variant ERβcx as Prognostic Predictors in Human Prostatic CancerBiochemical and Biophysical Research Communications, 2001
- Ligand-Independent Recruitment of SRC-1 to Estrogen Receptor β through Phosphorylation of Activation Function AF-1Molecular Cell, 1999
- High-dose intravenous estrogen therapy in advanced prostatic carcinomaUrology, 1989